Clinical application of tirofiban in patients with acute coronary artery syndrome

Xiao Min,Chen Zhangqiang,Liu Bin

DOI: https://doi.org/10.3969/j.issn.1006-2238.2008.12.008

2008-01-01

Abstract:Objective To evaluate the safety and efficacy of tirofiban,a specific inhibitor of the platelet glycoprotein Ⅱb/Ⅲa receptor,in the treatment of acute coronary syndrome.Methods A total of 62 patient s were randomly assigned in a double-blind manner to receive convention therapy, or tirofiban plus convention therapy.Patients received convention therapy if its use was not contraindicated.The composite primary end point consisted of death,myocardial infarction,or ref ractory ischemia.Results The frequency of the composite primary end point at 30 days was lower among the patients who received tirofiban plus convention therapy than among those who received convention therapy lone(9.7 percent vs 29.1 percent:P< 0.01).The rates of the other composite end point in the tirofiban plus convention therapy group were also lower than those in the convention therapy only group at 7,14 days and at 30 days).There were no difference in the incidence of bleeding or platelet decrease between two groups.Conclusion Tirofiban may further lower the incidence of ischemic events in patients with acute coronary syndrome on the basis of standard treatments in ACS,and hemorrhage complications do not increase,It was safety and efficacy, however its long term efficacy and side effects require further investigation.